Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 6.25 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $2.04 million which missed the analyst consensus estimate of $8.10 million by 74.79 percent. This is a 92.50 percent decrease over sales of $27.23 million the same period last year.
Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.